Clinical Trials Logo

Filter by:
NCT ID: NCT06167915 Not yet recruiting - SARS-CoV-2 Clinical Trials

Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine (CHO Cell)LYB002V14 in Booster Vaccination

Start date: December 26, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, blinded, and dose escalation phase I trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety and immunogenicity of Recombinant COVID-19 Trivalent (XBB.1+BQ.1.1+Prototype) Protein Vaccine (CHO Cell)(LYB002V14).

NCT ID: NCT06166589 Not yet recruiting - Clinical trials for Previously AG Chemotherapy Treated Pancreatic Cancer

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, phase II clinical study investigating second-line Zimberelimab and SIROX chemotherapy for patient with previously AG chemotherapy treated pancreatic cancer.

NCT ID: NCT06166472 Not yet recruiting - Clinical trials for Advanced Malignant Solid Tumor

A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

Start date: December 12, 2023
Phase: Phase 1
Study type: Interventional

This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor

NCT ID: NCT06166147 Not yet recruiting - Pancreatic Cancer Clinical Trials

A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection

Start date: December 22, 2023
Phase:
Study type: Observational

This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from clinically-annotated individuals.

NCT ID: NCT06165991 Not yet recruiting - Clinical trials for Postoperative Analgesia

Efficacy and Safety of Liposomal Bupivacaine in Thoracic Paravertebral Nerve Block

Start date: June 1, 2024
Phase: Phase 4
Study type: Interventional

I. Research purpose 1.1 Main Objective: To investigate the efficacy and safety of bupivacaine liposome thoracic paravertebral nerve block combined with drainage tube analgesia for postoperative analgesia after thoracoscopic lobectomy 1.2 Secondary objective: To investigate the efficacy and safety of drainage tube analgesia after thoracoscopic lobectomy 1.3 Exploratory Objective: To investigate the noninferiority of bupivacaine liposomes in thoracic paravertebral nerve block with standard bupivacaine

NCT ID: NCT06165887 Not yet recruiting - Clinical trials for Moderate-to-severe Psoriasis

The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance

Start date: February 2024
Phase:
Study type: Observational

Psoriasis is a common chronic and systemic immune-mediated disease, induced by a combination of genetic and environmental effects. The increasingly worrying question is the negative impact on patients' sleep, which has become an important comorbidity of psoriasis. To investigate the causal relationship between psoriasis and sleep status, a prospective cohort study will be conducted by separating moderate-to-severe psoriasis patients and healthy individuals into distinct cohorts in order to observe their sleep status.

NCT ID: NCT06165822 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

Start date: December 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.

NCT ID: NCT06164379 Not yet recruiting - Clinical trials for Primary Aldosteronism

Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

FAVOR
Start date: December 16, 2023
Phase: Phase 4
Study type: Interventional

To study the efficacy and safety of finerenone vs. spironolactone in patients with primary aldosteronism

NCT ID: NCT06164314 Not yet recruiting - Clinical trials for Postoperative Delirium

Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors

Start date: January 25, 2024
Phase: N/A
Study type: Interventional

Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium

NCT ID: NCT06164093 Not yet recruiting - Bronchiectasis Clinical Trials

Follow-up Study of Autologous Transplantation of P63+ Lung Progenitor Cells for Treatment of Bronchiectasis

Start date: November 30, 2023
Phase: N/A
Study type: Interventional

This is the follow-up study of autologous transplantation of P63+ lung progenitor cells (LPCs) for treatment of bronchiectasis (NCT03655808). Bronchiectasis is the consequence of chronic suppurative inflammation and fibrosis of the bronchial tubes and the surrounding lung tissues. This seriously damages the muscular and elastic tissues of the bronchial walls, leading to deformation and permanent dilatation of the bronchial tubes. Histopathological damage to the patient's lungs is irremediable. However, there is no effective drug for rebuilding the damaged lung tissue structure, and thus cannot fully restore normal lung function. Lung progenitor cells, located in the basal position of the bronchial epithelium, express the P63 and Keratin-5 (KRT5) marker genes. These cells are active in division and migration, continuously generating new cells to replace other types of dead epithelial cells. They exhibit functional plasticity and can directly repair bronchial and alveolar structures. P63+ LPCs can be extracted by fibreoptic brushing and then isolated, purified and expanded on a large scale using appropriate methods. Currently, preclinical studies and some pilot clinical trials have shown that these cells can successfully repair damaged lungs, improve lung function and have a favourable safety profile. To further investigate the therapeutic mechanism of P63+ LPCs, RNA sequencing will be performed on the remaining LPCs previously transplanted back into the patients. Additionally, to confirm the existence of LPCs in the lung tissue of bronchiectasis patients, the pathological sections of lung tissue samples from patients who had received surgical resection of the lesions, will be subjected to fluorescence staining.